Work

The Impact of TP53 Mutations and Use of the TP53-Mutation-Reactivating Agent APR-246 on Metastatic Castrate-Sensitive Prostate Cancer

Year: 2023

Type: article

Study design: Observational Study

Source: International Journal of Radiation Oncology*Biology*Physics

DOI: 10.1016/j.ijrobp.2023.06.1621

Authors: T. Hoang, P. Sutera, T. Nguyen, J.H. Chang, S. Jagtap, Y. Song, A. Shetty, D.D. Chowdhury, A. Chan, F.A.A. Carrieri, D. Song, T.L. DeWeese, A. Lafargue, K. Van der Eecken, F. Bunz, P. Ost, P.T. Tran, M.P. Deek

Institutions: Johns Hopkins University, University of Maryland, Baltimore, Johns Hopkins Medicine, Ghent University, Ghent University Hospital, Rutgers Cancer Institute

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: AstraZeneca, International Association for the Study of Lung Cancer, RefleXion Medical, Varian Medical Systems, Janssen Scientific Affairs, NRG Oncology, ViewRay, Astellas Pharma, Ipsen, School of Medicine, Duke University

OpenAlex ID: W4387207245

FWCI:

Cites:

Cited by:

Related to: 10